SCHEMBL6301924

SCHEMBL6301924

COc1cccc(CCC(=O)O)c1CC(C)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CTSG P08311 1/20 0.43
CMA1 P23946 1/20 0.43
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
LTB4R Q15722 1/20 0.42
LTB4R2 Q9NPC1 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FFAR1 O14842 2/20 0.41
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300266 0.87 CYP4F2 (0.49) MEN1KMT2ACRHBPCRHR2ATM
SCHEMBL6300158 0.82 L3MBTL1 (0.47) MEN1KMT2ACRHBPCRHR2ATM
SCHEMBL6301961 0.80 ATM (0.47) LMNAMEN1KMT2ACRHBPCRHR2
SCHEMBL26046334 0.79 LMNA (0.47) LMNALTB4RLTB4R2FFAR1HPGD
SCHEMBL6301275 0.79 HPGD (0.49) MEN1KMT2ACRHBPCRHR2ALDH1A1
SCHEMBL362209 0.77 LMNA (0.59) LMNAFFAR1HPGDNPSR1
SCHEMBL29590071 0.77 LMNA (0.59) LMNAFFAR1HPGDNPSR1
Hydrochloric Acid SCHEMBL7413528 0.76 LMNA (0.57) LMNAFFAR1HPGDNPSR1
SCHEMBL6307957 0.73 KDM4E (0.59) LMNAMEN1KMT2AATMALDH1A1
SCHEMBL6307944 0.73 KDM4E (0.59) LMNAMEN1KMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943183-B2 5-substituted tetralones as inhibitors of ras farnesyl transferase PFIZER INC (US) 2005-09-13 US disclosed
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase WARNER-LAMBERT COMPANY 2004-03-04 US disclosed
EP-1276725-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2003-01-22 EP disclosed
WO-2001079180-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase PTAR1, FNTA, GGPS1 LMNA 3627/4885MEN1 3391/4885KMT2A 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.